HOME¡¡¡¡¡¡PRODUCTS¡¡¡¡¡¡NEWS¡¡¡¡¡¡MESSAGES¡¡¡¡¡¡ABOUT US¡¡¡¡¡¡CONTACT US
 
 
PRODUCTS
Pharmaceutical Intermediates
Organic Intermediates
Food Additive
Imidazoles
API
Caine
CONTACT
 
Add:Room C815, Tongtai Building, 130 Zhonghua North Street, Shijiazhuang, Hebei, China.
Tel:0086 13111598319
Web:www.hbsaixin.com
 
Caine Your current location£ºHome - Products - Caine
 
LIDOCAINE CAS 137-58-6
 

Chemical & Physical Properties

Common Name Lidocaine

CAS Number 137-58-6

Purity 99%

Molecular Weight 234.337

Density 1.0¡À0.1 g/cm3

Boiling Point 372.7¡À52.0 ¡ãC at 760 mmHg

Molecular Formula C14H22N2O

Melting Point 66-69¡ãC

Flash Point 179.2¡À30.7 ¡ãC

Packing
1kg/Aluminum foil bag, inner double plastic bags

25kg/Fiber drum, inner double plastic bags

Shipping way

1. Ship by DHL/ FedEx/ UPS/EMS
2. Ship by special line if you can not make clearance when goods reach your customs
3. Ship by air/ sea

Use of Lidocaine

Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.Target: Lidocaine is a common local anesthetic and antiarrhythmic drug. Lidocaine is used topically to relieve itching, burning and pain from skin inflammations, injected as a dental anesthetic or as a local anesthetic for minor surgery. Lidocaine, the first amino amide¨Ctype local anesthetic, was first synthesized under the name xylocaine by Swedish chemist Nils Lofgren in 1943. His colleague Bengt Lundqvist performed the first injection anesthesia experiments on himself.Lidocaine is approximately 95% metabolized (dealkylated) in the liver by CYP3A4 to the pharmacologically-active metabolites monoethylglycinexylidide (MEGX) and then subsequently to the inactive glycine xylidide. MEGX has a longer half life than lidocaine but also is a less potent sodium channel blocker. The elimination half-life of lidocaine is approximately 90¨C120 minutes in most patients. This may be prolonged in patients with hepatic impairment (average 343 minutes) or congestive heart failure (average 136 minutes).

 
Previous£º LEVOBUPIVACAINE HCL CAS 27262-48-2 ¡¡Next£º PROCAINE CAS 59-46-1